Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
The companies press on with vilastobart and IMPT-314... up to a point.
Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
Could a new ADC project distract attention away from evorpacept?
